// App-Quantinova.ai

P4-01-13 : CTC enumeration and characterization has predictive and prognostic implications in patients with metastatic breast cancer treated with exemestane plus the mTOR inhibitor everolimus

Researchers

Presenter

  • Agelaki S

Principal Investigators

  • Mavroudis D

  • Spiliotaki MPolitaki EPapadaki MA

  • Apostolaki S

  • Nikolaou C

  • Georgoulias V

Medical Centers

  • University Hospital of Heraklion, Crete, Greece

  • Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Greece

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Peripheral blood mononuclear cell

  • Circulating tumor cells

  • Proliferation marker protein Ki-67

  • Human epidermal growth factor receptor 2

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Everolimus

  • Exemestane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved